Optimizing technology for cervical cancer screening in high-resource settings

References

• Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine24(Suppl. 3), 63–70 (2006).
   Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine24(Suppl. 3), 11–25 (2006).
   Web of Science ®Google Scholar
• McDougall JA, Madeleine MM, Daling JR, Li CI. Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992–2003. Cancer Causes Control18(10), 1175–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Scarinci IC, Garcia FA, Kobetz E et al. Cervical cancer prevention: new tools and old barriers. Cancer116(11), 2531–2542 (2010).
   PubMed Web of Science ®Google Scholar
• Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med.132(10), 810–819 (2000).
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 109: Cervical cytology screening. Obstet. Gynecol.114(6), 1409–1420 (2009).
   PubMedGoogle Scholar
• Murphy KJ, Howlett R. Canadian Consensus Guidelines on Human Papillomavirus: Chapter 5: Screening for cervical cancer. J. Obstet. Gynaecol. Can.29(8), S27–S36 (2007).
   PubMedGoogle Scholar
• Arbyn M, Anttila A, Jordan J et al. European guidelines for quality assurance in cervical cancer screening. Second edition – summary document. Ann. Oncol.21(3), 448–458 (2010).
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am. J. Obstet. Gynecol.197(6), 566–571 (2007).
   PubMedGoogle Scholar
• National Institute for Clinical Excellence (NICE). Guidance on the use of liquid-based cytology for cervical screening (NICE), London, UK (2003).
   Google Scholar
• Ronco G, Cuzick J, Pierotti P et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ335(7609), 28 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn L, Wang C, Tsai WY, Wright TC, Denny L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS24(16), 2553–2561 (2010).
   PubMed Web of Science ®Google Scholar
• Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J. Natl Cancer Inst.102(20), 1557–1567 (2010).
   PubMedGoogle Scholar
• Herrero R, Ferreccio C, Salmeron J et al. New approaches to cervical cancer screening in Latin America and the Caribbean. Vaccine26(Suppl. 11), L49–L58 (2008).
   Google Scholar
• Tsu VD, Pollack AE. Preventing cervical cancer in low-resource settings: how far have we come and what does the future hold? Int. J. Gynaecol. Obstet.89(Suppl. 2), S55–S59 (2005).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int. J. Gynaecol. Obstet.89(Suppl. 2), S4–S12 (2005).
   PubMed Web of Science ®Google Scholar
• Mahe C, Gaffikin L. Screening test accuracy studies: how valid are our conclusions? Application to visual inspection methods for cervical screening. Cancer Causes Control16(6), 657–666 (2005).
   PubMed Web of Science ®Google Scholar
• Blumenthal PD, Lauterbach M, Sellors JW, Sankaranarayanan R. Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy. Int. J. Gynaecol. Obstet.89(Suppl. 2), S30–S37 (2005).
   Web of Science ®Google Scholar
• Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine26(Suppl. 10), K29–K41 (2008).
   PubMed Web of Science ®Google Scholar
• Stuart G, Taylor G, Bancej CM et al. Report of the 2003 pan-Canadian forum on cervical cancer prevention and control. J. Obstet. Gynaecol. Can.26(11), 1004–1028 (2004).
   PubMedGoogle Scholar
• Stuart G, Taylor G. Report of the 2003 pan-Canadian forum on cervical cancer prevention and control. J. Obstet. Gynaecol. Can.26(11), 1004–1028 (2004).
   PubMedGoogle Scholar
• Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA287(16), 2114–2119 (2002).
   PubMed Web of Science ®Google Scholar
• ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol.188(6), 1393–1400 (2003).
   PubMed Web of Science ®Google Scholar
• ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol.188(6), 1383–1392 (2003).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med.127(8), 946–949 (2003).
   PubMedGoogle Scholar
• Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J. Cell. Mol. Med.13(4), 648–659 (2009).
   PubMed Web of Science ®Google Scholar
• Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am. J. Obstet. Gynecol.200(4), 422.e421–e429 (2009).
   Google Scholar
• Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine24(Suppl. 3), 78–89 (2006).
   Web of Science ®Google Scholar
• Paraskevaidis E, Arbyn M, Sotiriadis A et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat. Rev.30(2), 205–211 (2004).
   PubMed Web of Science ®Google Scholar
• Solomon D, Papillo JL, Davey DD. Statement on HPV DNA test utilization. Acta Cytol.53(3), 247–248 (2009).
   PubMed Web of Science ®Google Scholar
• Dillner J, Rebolj M, Birembaut P et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ337, a1754 (2008).
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer111(2), 278–285 (2004).
   PubMed Web of Science ®Google Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines8(12), 1663–1679 (2009).
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J. Infect. Dis.199(7), 926–935 (2009).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374(9686), 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Xiridou M, Coupe VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am. J. Epidemiol.171(7), 817–825 (2010).
   PubMed Web of Science ®Google Scholar
• Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer106(6), 896–904 (2003).
   PubMed Web of Science ®Google Scholar
• Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine24(Suppl. 3), 171–177 (2006).
   PubMedGoogle Scholar
• Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res.40(6), 478–485 (2009).
   PubMed Web of Science ®Google Scholar
• Rogoza RM, Ferko N, Bentley J et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine26(Suppl. 5), F46–F58 (2008).
   Google Scholar
• Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br. J. Cancer98(1), 15–21 (2008).
   PubMed Web of Science ®Google Scholar
• Kiviat NB, Hawes SE, Feng Q. Screening for cervical cancer in the era of the HPV vaccine – the urgent need for both new screening guidelines and new biomarkers. J. Natl Cancer Inst.100(5), 290–291 (2008).
   PubMedGoogle Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet370(9590), 890–907 (2007).
   PubMed Web of Science ®Google Scholar
• Anttila A, Kotaniemi-Talonen L, Leinonen M et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ340, c1804 (2010).
   PubMedGoogle Scholar
• Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med.357(16), 1579–1588 (2007).
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet370(9601), 1764–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med.357(16), 1589–1597 (2007).
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol.11(3), 249–257 (2010).
   PubMed Web of Science ®Google Scholar
• Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev. Mol. Diagn.8(5), 599–605 (2008).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Ronco G, Meijer CJ, Naucler P. Trials comparing cytology with human papillomavirus screening. Lancet Oncol.10(10), 935–936 (2009).
   PubMed Web of Science ®Google Scholar
• Franco EL. Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J. Natl Cancer Inst. Monogr.31, 89–96 (2003).
   Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• IARC Working Group on the Evaluation of Cancer Preventive Strategies. IARC Handbooks of Cancer Prevention. Volume 10: Cervix Cancer Screening. IARC Press, Lyon, France (2005).
   Google Scholar
• Arbyn M, Kyrgiou M, Simoens C et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ337, a1284 (2008).
   PubMed Web of Science ®Google Scholar
• Franco EL, Coutlee F, Ferenczy A. Integrating human papillomavirus vaccination in cervical cancer control programmes. Public Health Genomics12(5–6), 352–361 (2009).
   PubMedGoogle Scholar
• Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine26(Suppl. 1), A16–A23 (2008).
   PubMed Web of Science ®Google Scholar
• Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst.101(23), 1612–1623 (2009).
   PubMedGoogle Scholar
• Ogilvie GS, van Niekerk DJ, Krajden M et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL trial). BMC Cancer10, 111 (2010).
   PubMedGoogle Scholar
• Kulasingam SL, Rajan R, St Pierre Y, Atwood CV, Myers ER, Franco EL. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost–effectiveness analysis. BMC Med.7, 69 (2009).
   PubMedGoogle Scholar
• Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost–effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol. Oncol.119(2), 237–242 (2010).
   PubMedGoogle Scholar
• Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost–effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J. Natl Cancer Inst.100(5), 308–320 (2008).
   PubMed Web of Science ®Google Scholar
• Berkhof J, Coupe VM, Bogaards JA et al. The health and economic effects of HPV DNA screening in The Netherlands. Int. J. Cancer127(9), 2147–2158 (2010).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Szarewski A, Mesher D et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int. J. Cancer122(10), 2294–2300 (2008).
   PubMed Web of Science ®Google Scholar
• Kotaniemi-Talonen L, Anttila A, Malila N et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur. J. Cancer44(4), 565–571 (2008).
   PubMedGoogle Scholar
• Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol.10(7), 672–682 (2009).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Nene BM, Dinshaw KA et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer116(4), 617–623 (2005).
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA290(6), 781–789 (2003).
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst.97(14), 1072–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev.17(10), 2536–2545 (2008).
   PubMed Web of Science ®Google Scholar
• Cuschieri KS, Cubie HA, Whitley MW et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J. Clin. Pathol.57(1), 68–72 (2004).
   PubMed Web of Science ®Google Scholar
• Monsonego J, Hudgens MG, Zerat L et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening (The FASE study). Int. J. Cancer DOI: 10.1002/ijc.25726 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat. Rev.35(3), 210–220 (2009).
   PubMed Web of Science ®Google Scholar
• Haidopoulos D, Partsinevelos GA, Vlachos GD et al. p16 INK4A is a strong biomarker for cervical intraepithelial neoplasia and invasive cervical carcinoma: a reappraisal. Reprod. Sci.16(7), 685–693 (2009).
   PubMedGoogle Scholar
• Mao C, Balasubramanian A, Yu M et al. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int. J. Cancer120(11), 2435–2438 (2007).
   PubMedGoogle Scholar
• Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer111(1), 58–66 (2007).
   PubMed Web of Science ®Google Scholar
• Denton KJ, Bergeron C, Klement P, Trunk MJ, Keller T, Ridder R. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am. J. Clin. Pathol.134(1), 12–21 (2010).
   PubMed Web of Science ®Google Scholar
• Meyer JL, Hanlon DW, Andersen BT, Rasmussen OF, Bisgaard K. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: correlation with biopsy follow-up results. Cancer111(2), 83–92 (2007).
   PubMedGoogle Scholar
• Holladay EB, Logan S, Arnold J, Knesel B, Smith GD. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer108(6), 451–461 (2006).
   PubMedGoogle Scholar
• Carozzi F, Cecchini S, Confortini M et al. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. Cancer108(2), 119–123 (2006).
   PubMedGoogle Scholar
• Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix. Acta Cytol.48(2), 173–180 (2004).
   PubMedGoogle Scholar
• Guo M, Hu L, Baliga M, He Z, Hughson MD. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am. J. Clin. Pathol.122(6), 894–901 (2004).
   PubMed Web of Science ®Google Scholar
• Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol. Oncol.91(1), 201–208 (2003).
   PubMed Web of Science ®Google Scholar
• Zeng WJ, Li Y, Fei HL et al. The value of p16ink4a expression by fluorescence in situ hybridization in triage for high risk HPV positive in cervical cancer screening. Gynecol. Oncol.120(1), 84–88 (2011).
   PubMedGoogle Scholar
• Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am. J. Surg. Pathol.34(8), 1077–1087 (2010).
   PubMed Web of Science ®Google Scholar
• Carozzi F, Confortini M, Dalla PP et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol.9(10), 937–945 (2008).
   PubMed Web of Science ®Google Scholar
• Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis. Markers23(4), 315–330 (2007).
   PubMed Web of Science ®Google Scholar
• Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev.17(11), 3033–3042 (2008).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet362(9399), 1871–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low Genit. Tract. Dis.11(4), 201–222 (2007).
   PubMedGoogle Scholar
• Sasieni P, Castle PE, Cuzick J. Further analysis of the ARTISTIC trial. Lancet Oncol.10(9), 841–842 (2009).
   PubMedGoogle Scholar
• Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. J. Low Genit. Tract. Dis.12(1), 1–7 (2008).
   PubMed Web of Science ®Google Scholar
• Howlett RI, Miller AB, Pasut G, Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. Prev. Med.48(5), 432–437 (2009).
   PubMedGoogle Scholar
• Human Papillomavirus (HPV): Information about the Human Papillomavirus (HPV) Immunisation Program funded under the Immunise Australia Program.
   Google Scholar
• Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol.197(4), 356.e351–e356 (2007).
   PubMed Web of Science ®Google Scholar
• Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J. Natl Cancer Inst.92(10), 818–825 (2000).
   PubMed Web of Science ®Google Scholar
• Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev.9(9), 945–951 (2000).
   PubMed Web of Science ®Google Scholar
• Schiffman M, Herrero R, Hildesheim A et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA283(1), 87–93 (2000).
   PubMed Web of Science ®Google Scholar
• Belinson J, Qiao YL, Pretorius R et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol. Oncol.83(2), 439–444 (2001).
   PubMed Web of Science ®Google Scholar
• Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int. J. Gynaecol. Obstet.72(1), 47–53 (2001).
   PubMed Web of Science ®Google Scholar
• Clavel C, Masure M, Bory JP et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer84(12), 1616–1623 (2001).
   PubMed Web of Science ®Google Scholar
• Belinson JL, Qiao YL, Pretorius RG et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int. J. Gynecol. Cancer13(6), 819–826 (2003).
   PubMedGoogle Scholar
• Coste J, Cochand-Priollet B, de Cremoux P et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ326(7392), 733 (2003).
   PubMedGoogle Scholar
• Petry KU, Menton S, Menton M et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer88(10), 1570–1577 (2003).
   PubMed Web of Science ®Google Scholar
• Salmeron J, Lazcano-Ponce E, Lorincz A et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control14(6), 505–512 (2003).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Chatterji R, Shastri SS et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int. J. Cancer112(2), 341–347 (2004).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Thara S, Sharma A et al. Accuracy of conventional cytology: results from a multicentre screening study in India. J. Med. Screen.11(2), 77–84 (2004).
   PubMed Web of Science ®Google Scholar
• Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br. J. Cancer93(5), 575–581 (2005).
   PubMed Web of Science ®Google Scholar
• Sarian LO, Derchain SF, Naud P et al. Evaluation of visual inspection with acetic acid (VIA), Lugol’s iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J. Med. Screen.12(3), 142–149 (2005).
   PubMed Web of Science ®Google Scholar
• Almonte M, Ferreccio C, Winkler JL et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int. J. Cancer121(4), 796–802 (2007).
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl Cancer Inst.100(7), 492–501 (2008).
   PubMed Web of Science ®Google Scholar